Sign In
Buy LFCR
$5.67
+0.220 (+4.04%)
At Close: Jun 03, 2026
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
07:05am, Tuesday, 02'nd Jun 2026
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn.
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
07:05am, Thursday, 21'st May 2026
CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO�
Lifecore Biomedical to Participate at CDMO Live Europe
04:05pm, Tuesday, 12'th May 2026
CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDM
Lifecore Biomedical, Inc. (LFCR) Q1 2026 Earnings Call Transcript
05:41pm, Wednesday, 06'th May 2026
Lifecore Biomedical, Inc. (LFCR) Q1 2026 Earnings Call Transcript
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update
07:05am, Wednesday, 06'th May 2026
-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter 2026 -- -- Cost Containment Initiatives Continue to Drive Down Expenses -- Conference Call Today at
Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026
04:05pm, Wednesday, 29'th Apr 2026
CHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“C
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 22'nd Apr 2026
CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO�
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Receives Average Recommendation of “Hold” from Analysts
04:14am, Saturday, 11'th Apr 2026
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR - Get Free Report) have received a consensus recommendation of "Hold" from the five brokerages that are covering the firm, MarketBeat reports. One res
Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
08:00am, Wednesday, 08'th Apr 2026
CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDM
SAINT PAUL, Minn., April 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP and The Rosen Law Firm, P.A. announce that the United States District Court District of Minnesota has approved the following announc
Lifecore Biomedical (NASDAQ:LFCR) and Kezar Life Sciences (NASDAQ:KZR) Head-To-Head Review
01:23am, Thursday, 02'nd Apr 2026
Kezar Life Sciences (NASDAQ: KZR - Get Free Report) and Lifecore Biomedical (NASDAQ: LFCR - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the tw
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 26'th Mar 2026
CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO�
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
07:00am, Thursday, 26'th Mar 2026
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
07:00am, Monday, 23'rd Mar 2026
-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial R
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lifecore Biomedical, Inc. The investigation focuses on Lifecore Biomedica
